This is a routine pre-planned sale by a director under a 10b5-1 plan. No immediate trading signal. Monitor for any actual Form 4 filings to confirm execution, but no action warranted.
CELC drugs
CELC drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 4 $144.98entry
- T+1 · 7mo ago −2.27%α −3.06% · $141.69
- T+5 · 6mo ago −13.34%α −16.28% · $125.64
- T+20 · 6mo ago −15.19%α −20.83% · $122.96
- T+60 · 4mo ago −42.57%α −44.43% · $83.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director David Dalvey filed a Form 144 notice of intent to sell 25,000 shares of Celcuity Inc. common stock, with an approximate market value of $3,517,000 based on the filing date. The sale is planned under a Rule 10b5-1 trading plan established on August 19, 2025, indicating a pre-planned, non-discretionary transaction. Given the director role (not CEO/CFO), the pre-planned nature, and the relatively small proportion relative to the company's $6.1B market cap, this filing is routine and carries no material signal.
Key Facts
- Insider: David Dalvey, Director
- Shares to be sold: 25,000 shares of common stock
- Approximate market value: $3,517,000
- Sale intended under Rule 10b5-1 plan established on August 19, 2025
- Filing date: May 4, 2026
- Broker: RBC Capital Markets LLC
Financial Impact
Proposed sale of 25,000 shares worth approximately $3.5 million, representing a small fraction of the company's $6.1B market cap.
Risk Factors
- Insider selling could be misinterpreted by the market as a negative signal, though the 10b5-1 plan mitigates this.
- No material risk to the company from this transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001000275-26-000043 |
| Document: 0001000275-26-000043-index.html | 0001000275-26-000043 |
| Document: 0001000275-26-000043.txt | 0001000275-26-000043 |
Track record
26 reports on CELC
7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
- Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
- Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
- Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
- Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
- Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers